

Improving Outpatient Antimicrobial Stewardship Through Pharmacist Assessment of Urine Cultures via a Mature Culture Follow-up Program

Address correspondence to:

Benjamin Muron, PharmD
benjamin.muron@trinity-health.org

Benjamin Muron, PharmD; Heather Draper, PharmD, BCPS, BCEMP; Kamah Ellena, PharmD, BCCCP; Aidan Yetsko, PharmD; Tyler Mitzner, PharmD; Lisa Dumkow, PharmD, BCIDP

Trinity Health Grand Rapids, Grand Rapids, MI

Background

- Since March 2014, Trinity Health Grand Rapids (THGR) has operated under a collaborative practice agreement (CPA) that allows pharmacistled culture follow up, including symptom assessment for patients discharged from emergency department (ED) and urgent care (UC) sites. This CPA supports not prescribing antibiotics for patients who are asymptomatic at follow up
- No previous studies have assessed clinical outcomes of a mature culture follow-up program that includes antimicrobial deprescribing or nonprescribing for patients with positive urine cultures

Objectives

Primary

 Compare clinical outcomes associated with deprescribing and non-prescribing antibiotics at follow-up for patients with a positive urine culture but with resolved or absent symptoms of urinary tract infections (UTIs) versus the standard of care

Secondary

 Assess days of therapy, safety outcomes, and workload with pharmacist deprescribing and nonprescribing

Methods

Design

- Retrospective cohort study
- January 1, 2020 December 31, 2024


Patient Population

- Females ≥18 years with a positive urine culture contacted by the pharmacist-led culture follow-up team
- 200 patients to detect approximately a 15% difference between groups (100 in each arm)

Most Common Exclusion Criteria

- Receipt of parenteral antibiotics before oral antibiotics
- Recurrent UTI

Results



Patient Characteristics

Group	Standard of Care (n = 97)	De/Non-prescribed (n = 117)	p-value
Initial Visit Location (n, %)Emergency DepartmentUrgent Care	47 (48.5) 50 (51.5)	83 (70.9) 34 (29.1)	0.001
Reported symptoms at initial visit, n (%)	81 (83.5)	62 (53)	< 0.001
Diagnosis of acute cystitis (n, %)	38 (39.2)	26 (22.2)	0.007
 Empiric Antibiotic Prescribed (n, %) Cephalexin Nitrofurantoin Sulfamethoxazole Trimethoprim 	36 (37.1) 16 (44.4) 17 (47.2) 3 (8.3)	30 (25.6) 18 (60) 11 (36.7) 1 (3.3)	0.392
Initial duration of antibiotic (days), mean (±SD)	5.8 (±1.6)	5.9 (±1.5)	0.747
Appropriate duration of antibiotics prescribed (n, %)	26 (72.2)	23 (76.7)	0.681

Follow-up Characteristics

Group	Standard of Care (n = 97)	De/Non-prescribed (n = 117)	p-value
Organism not susceptible to empiric agents (n, %)	35 (97.2)	27 (90)	0.323
Reported symptoms at follow-up, n (%)	89 (91.8)	6 (5.1)	< 0.001
For no symptoms reported, intervention, n (%)			
 Deprescribed 	_	2 (1.7)	-
 Not Prescribed 	_	115 (98.3)	

Results

- The mean duration of antibiotics given by pharmacists at follow up was 4.9 days
- There were no cases of *Clostridioides difficile* within 30 days of follow up
- There was one reported adverse event of a mild allergy in the standard of care group
- For both groups, time to pharmacist follow up occurred approximately 2.5 days later, with a median of 1 contact attempt made and a median of 15 minutes spent on each intervention

Discussion

- Not prescribing antibiotics at follow up for asymptomatic patients despite a positive urine culture is an appropriate stewardship intervention supported by national guidelines
- Improved diagnostic stewardship is needed.
 Decreasing inappropriate urinalysis and cultures can prevent treating asymptomatic patients
- An opportunity exists for CPA expansion to allow for direct deprescribing practice as this is not outlined in the current CPA

Conclusions

There was no difference in clinical or safety outcomes when comparing deprescribing or not prescribing antibiotic practices to the standard of care for treating UTIs and asymptomatic bacteriuria in a long-standing pharmacist-driven ED culture follow up program

References

- Dumkow LE, Beuschel TS, Brandt KL. Infect Dis Ther. 2017;6:453-59.
- 2. Nicolle, L. E., et al. Clinical Infectious Diseases, 68(10), 1611–1615.
- Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. JAMA. 2016;315(17):1864-1873.

The authors of this presentation have nothing to disclose concerning possible financial or personal relationship with commercial entities that may have a direct or indirect interest in the subject matter of the presentation.